- Peptide Substrates
- Binding Proteins
- Secondary Antibodies
- Regulatory proteins
- 脂类激酶
- 双加氧酶与蛋白质
- 脂质底物
- E2
- Assay Buffer and Co-factors
- Methyltransferases
- Acetyltransferases
- Transcription Proteins
- COVID-19 ELISA Kits
- Tau Proteins
- Microtubule & Actin Associated Proteins
- Carbohydrate Substrates
- COVID-19 Proteins
- Chemokines
- 标记抗体
- 授予称号
- E3
Overview:
The Anti-NOTCH 2 antibody recognizes NOTCH 2 that is synthesized in the endoplasmic reticulum as an inactive form which is proteolytically cleaved by a furin-like convertase (S1 cleavage) in the trans-golgi network before it reaches the plasma membrane to yield an active, ligand-accessible form. Cleavage results in a C-terminal fragment N(TM) and a N-terminal fragment N(EC). Following ligand binding, it is cleaved (S2 cleavage) by TNF-alpha converting enzyme (TACE) to yield a membrane-associated intermediate fragment called NOTCH extracellular truncation (NEXT). This fragment is then cleaved by presenilin-dependent gamma-secretase (S3 cleavage) to release the intracellular domain (NICD) from the membrane.